ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biologic response modifiers"

  • Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting

    Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over

    Jean-Pascal Roussy1, Louis Bessette2, Sasha Bernatsky3, Elham Rahme4 and Jean Lachaine1, 1Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada, 2Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, 3Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, 4Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada

    Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…
  • Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting

    Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study

    Diane Lacaille1, Michal Abrahamowicz2, Eric C. Sayre3 and John Esdaile4, 1Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, 2Clinical Epidemiology, McGill University, Montreal, QC, Canada, 3Arthritis Research Centre of Canada, Vancouver, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…
  • Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting

    Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients

    Cesar Vargas-Serafin1, Luis Aguilar-Lozano1, Jorge Padilla-Ibarra1, Carlos Sandoval-Castro1, Jose Dionisio Castillo-Ortiz1, Jorge Morales-Torres2, Claudia Hernandez2 and Cesar Ramos-Remus1, 1Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 2Rheumatology, Hospital Aranda de la Parra, Leon, Mexico

    Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…
  • Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting

    Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept

    Michele Hooper1, Deborah Wenkert2, Bojena Bitman3, Virgil C. Dias4, Yessinia Bartley5, Julie Wang6 and Julia R. Gage7, 1Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, 2Inflammation TA, Amgen Inc., Thousand Oaks, CA, 3Amgen, Inc., San Francisco, CA, 4Amgen Inc., Thousand Oaks, CA, 5Assent Consulting, Solana Beach, CA, 6Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, 7Gage Medical Writing, LLC, Oak Park, CA

    Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263).  In 2011, the…
  • Abstract Number: 388 • 2012 ACR/ARHP Annual Meeting

    Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry

    Chi Chiu Mok1, Cherry Kwan1, Helen Chan2, Ka Lai Lee3 and Lai-Shan Tam4, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Rehabilitation, Kowloon Hospital, Hong Kong, Hong Kong, Hong Kong, 3Medicine, Pamela Youde Eastern Hospital, Hong Kong, Hong Kong, 4Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

    Background/Purpose: To study the retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and the associated factors for drug withdrawal Methods: Data…
  • Abstract Number: 1569 • 2012 ACR/ARHP Annual Meeting

    Optimizing Care for Patients with Rheumatoid Arthritis Newly Treated with Biologics by Evaluating Health Status with AIMS-2

    Mie Fusama1, Hideko Nakahara2, Keisuke Kawamoto3, Satoko Nozato3, Midori Taguchi3, Kohji Nishioka3, Shinji Higa3, Eiji Takeuchi4, Kayoko Higashi5, Masao Yukioka6, Tsuyoshi Igarashi3, Taro Kuritani3, Keiji Maeda3 and Yasushi Miura7, 1Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 3Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 4Department of Orthopaedic Surgery, NTT West Osaka Hospital, Osaka, Japan, 5Division of nursing, NTT West Osaka Hospital, Osaka, Japan, 6Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, 7Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan

    Background/Purpose: Biologics significantly improve disease activity of rheumatoid arthritis (RA), however, patient global assessment (PGA) is not always improved in parallel with disease activity scores.…
  • Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting

    Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms

    Paul Emery1, Piotr Wiland2, Wolfgang Spieler3, Jean Dudler4, Stefanie Gaylord5, Theresa Williams5, Ronald Pedersen5, Andrew S. Koenig5, Bonnie Vlahos5 and Sameer Kotak6, 1Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, 2Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, 3Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 4Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, 5Department of Specialty Care, Pfizer Inc., Collegeville, PA, 6Department of Specialty Care, Pfizer Inc., New York, NY

    Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
  • Abstract Number: 1552 • 2012 ACR/ARHP Annual Meeting

    Clinical Correlates, Treatment Outcomes and Predictors of Vasculitis Associated with Rheumatoid Arthritis in the ‘Biologic Era’ : A Case-Control Study

    Ashima Makol1, Cynthia S. Crowson2, Eric L. Matteson3 and Kenneth J. Warrington1, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: 1.To determine the clinical presentation, treatment and outcomes of vasculitis (RV) associated with rheumatoid arthritis (RA) in the era of biologic use. 2. To…
  • Abstract Number: 1163 • 2012 ACR/ARHP Annual Meeting

    Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents

    Tomohiro Kubota1, Tsuyoshi Yamatou2, Yukiko Nonaka2, Harumi Akaike2, Tomokazu Nagakura3, Yuichi Yamasaki1, Tomoko Takezaki2, Yasuhito Nerome2, Hiroyuki Imanaka2 and Syuji Takei4, 1Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 2Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, 3Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, 4School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan

    Background/Purpose: Progression of joint damage is sometimes observed in JIA patients during the biologic therapy.  However, it is difficult to evaluate the radiographic progression by…
  • Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting

    Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study

    Ricardo A. G. Russo1 and Marìa M. Katsicas2, 1Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 2Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina

    Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology